APRE ▲ +8.2% - Aprea Therapeutics, Inc.
$APRE - Aprea Therapeutics Announces Interim Results From the Ongoing First-in-human Phase 1 Study of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors (ACESOT-1051) at the 38th EORTC-NCI-AACR Symposium in Barcelona
20-NOV-2026 09:00 AM ET
Share this post
More filings for $APRE
APRE ▼ -2.0% - Aprea Therapeutics, Inc.Nov 5, 2026APRE ▲ +4.8% - Aprea Therapeutics, Inc.Oct 16, 2026APRE ▲ +8.1% - Aprea Therapeutics, Inc.Sep 22, 2026APRE ▲ +2.5% - Aprea Therapeutics, Inc.Sep 10, 2026APRE ▲ +4.7% - Aprea Therapeutics, Inc.Aug 28, 2026APRE - Aprea Therapeutics, Inc. - SEC Filing Update (13-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 13, 2026
View full $APRE filing history →💬 Comments
Loading comments…
Leave a comment
